BACKGROUND: As the use of continuous glucose monitoring (CGM) increases, there is a need to better understand key metrics of time in range 70-180 mg/dL (TIR70-180) and hyperglycemia and how they relate to hemoglobin A1c (A1C). METHODS: Analyses were conducted utilizing datasets from four randomized trials encompassing 545 adults with type 1 diabetes (T1D) who had central-laboratory measurements of A1C. CGM metrics were calculated and compared with each other and A1C cross-sectionally and longitudinally. RESULTS: Correlations among CGM metrics (TIR70-180, time >180 mg/dL, time >250 mg/dL, mean glucose, area under the curve above 180 mg/dL, high blood glucose index, and time in range 70-140 mg/dL) were typically 0.90 or greater. Correlations of each metric with A1C were lower (absolute values 0.66-0.71 at baseline and 0.73-0.78 at month 6). For a given TIR70-180 percentage, there was a wide range of possible A1C levels that could be associated with that TIR70-180 level. On average, a TIR70-180 of 70% and 50% corresponded with an A1C of approximately 7% and 8%, respectively. There also was considerable spread of change in A1C for a given change in TIR70-180, and vice versa. An increase in TIR70-180 of 10% (2.4 hours per day) corresponded to a decrease in A1C of 0.6%, on average. CONCLUSIONS: In T1D, CGM measures reflecting hyperglycemia (including TIR and mean glucose) are highly correlated with each other but only moderately correlated with A1C. For a given TIR or change in TIR there is a wide range of possible corresponding A1C values.
BACKGROUND: As the use of continuous glucose monitoring (CGM) increases, there is a need to better understand key metrics of time in range 70-180 mg/dL (TIR70-180) and hyperglycemia and how they relate to hemoglobin A1c (A1C). METHODS: Analyses were conducted utilizing datasets from four randomized trials encompassing 545 adults with type 1 diabetes (T1D) who had central-laboratory measurements of A1C. CGM metrics were calculated and compared with each other and A1C cross-sectionally and longitudinally. RESULTS: Correlations among CGM metrics (TIR70-180, time >180 mg/dL, time >250 mg/dL, mean glucose, area under the curve above 180 mg/dL, high blood glucose index, and time in range 70-140 mg/dL) were typically 0.90 or greater. Correlations of each metric with A1C were lower (absolute values 0.66-0.71 at baseline and 0.73-0.78 at month 6). For a given TIR70-180 percentage, there was a wide range of possible A1C levels that could be associated with that TIR70-180 level. On average, a TIR70-180 of 70% and 50% corresponded with an A1C of approximately 7% and 8%, respectively. There also was considerable spread of change in A1C for a given change in TIR70-180, and vice versa. An increase in TIR70-180 of 10% (2.4 hours per day) corresponded to a decrease in A1C of 0.6%, on average. CONCLUSIONS: In T1D, CGM measures reflecting hyperglycemia (including TIR and mean glucose) are highly correlated with each other but only moderately correlated with A1C. For a given TIR or change in TIR there is a wide range of possible corresponding A1C values.
Entities:
Keywords:
continuous glucose monitoring; glucose time in range; type 1 diabetes
Authors: Richard M Bergenstal; Andrew J Ahmann; Timothy Bailey; Roy W Beck; Joan Bissen; Bruce Buckingham; Larry Deeb; Robert H Dolin; Satish K Garg; Robin Goland; Irl B Hirsch; David C Klonoff; Davida F Kruger; Glenn Matfin; Roger S Mazze; Beth A Olson; Christopher Parkin; Anne Peters; Margaret A Powers; Henry Rodriguez; Phil Southerland; Ellie S Strock; William Tamborlane; David M Wesley Journal: Diabetes Technol Ther Date: 2013-02-28 Impact factor: 6.118
Authors: Roger S Mazze; Ellie Strock; David Wesley; Sarah Borgman; Blaine Morgan; Richard Bergenstal; Robert Cuddihy Journal: Diabetes Technol Ther Date: 2008-06 Impact factor: 6.118
Authors: William V Tamborlane; Roy W Beck; Bruce W Bode; Bruce Buckingham; H Peter Chase; Robert Clemons; Rosanna Fiallo-Scharer; Larry A Fox; Lisa K Gilliam; Irl B Hirsch; Elbert S Huang; Craig Kollman; Aaron J Kowalski; Lori Laffel; Jean M Lawrence; Joyce Lee; Nelly Mauras; Michael O'Grady; Katrina J Ruedy; Michael Tansey; Eva Tsalikian; Stuart Weinzimer; Darrell M Wilson; Howard Wolpert; Tim Wysocki; Dongyuan Xing Journal: N Engl J Med Date: 2008-09-08 Impact factor: 91.245
Authors: Darrell M Wilson; Dongyuan Xing; Jing Cheng; Roy W Beck; Irl Hirsch; Craig Kollman; Lori Laffel; Jean M Lawrence; Nelly Mauras; Katrina J Ruedy; Eva Tsalikian; Howard Wolpert Journal: Diabetes Care Date: 2011-04-19 Impact factor: 19.112
Authors: Ananth U Nayak; Martin R Holland; David R Macdonald; Alan Nevill; Baldev M Singh Journal: Diabetes Care Date: 2011-06-29 Impact factor: 19.112
Authors: Roy W Beck; Irl B Hirsch; Lori Laffel; William V Tamborlane; Bruce W Bode; Bruce Buckingham; Peter Chase; Robert Clemons; Rosanna Fiallo-Scharer; Larry A Fox; Lisa K Gilliam; Elbert S Huang; Craig Kollman; Aaron J Kowalski; Jean M Lawrence; Joyce Lee; Nelly Mauras; Michael O'Grady; Katrina J Ruedy; Michael Tansey; Eva Tsalikian; Stuart A Weinzimer; Darrell M Wilson; Howard Wolpert; Tim Wysocki; Dongyuan Xing Journal: Diabetes Care Date: 2009-05-08 Impact factor: 19.112
Authors: David M Nathan; Judith Kuenen; Rikke Borg; Hui Zheng; David Schoenfeld; Robert J Heine Journal: Diabetes Care Date: 2008-06-07 Impact factor: 19.112
Authors: Santiago Rodríguez-Segade; Javier Rodríguez; José M García Lopez; Felipe F Casanueva; Félix Camiña Journal: Diabetes Care Date: 2012-09-06 Impact factor: 19.112
Authors: Elizabeth O Buschur; Kristen Campbell; Laura Pyle; Rachel Garcetti; Prakriti Joshee; Jamie K Demmitt; Janet K Snell-Bergeon; Sarit Polsky Journal: Diabetes Technol Ther Date: 2021-11 Impact factor: 6.118